학술논문
Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates.
Document Type
Academic Journal
Author
Prajjwal P; Department of Neurology Bharati Vidyapeeth Deemed University Pune India.; Marsool MDM; Department of Neurology, Al-Kindy College of Medicine University of Baghdad Baghdad Iraq.; Yadav V; Department of Internal Medicine Pt. B. D. S. Postgraduate Institute of Medical Sciences Rohtak India.; Kanagala RSD; Department of Internal Medicine Mamata Medical College Khammam Telangana India.; Reddy YB; Department of Internal Medicine Zaporozhyea State Medical University Zaporozhyea Ukraine.; John J; Department of Internal Medicine Dr. Somervell Memorial CSI Medical College and Hospital Neyyāttinkara India.; Lam JR; Department of Internal Medicine Cebu Institute of Medicine Cebu Philippines.; Karra N; Department of Internal Medicine Osmania Medical College Hyderabad Telangana India.; Amiri B; Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran.; Islam MU; Department of Internal Medicine Punjab Medical College Faisalabad Pakistan.; Nithya V; Department of Internal Medicine S. D. Asfendiyarov Kazakh National Medical University Almaty Kazakhstan.; Marsool ADM; Department of Neurology, Al-Kindy College of Medicine University of Baghdad Baghdad Iraq.; Gadam S; Mayo Clinic Rochester Minnesota USA.; Vora N; B. J. Medical College Ahmedabad India.; Hussin OA; Department of Medicine Almanhal University Academy of Science Khartoum Sudan.
Source
Publisher: John Wiley and Sons, Inc Country of Publication: United States NLM ID: 101728855 Publication Model: eCollection Cited Medium: Internet ISSN: 2398-8835 (Electronic) Linking ISSN: 23988835 NLM ISO Abbreviation: Health Sci Rep Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Background: Scleroderma, also referred to as systemic sclerosis, is a multifaceted autoimmune condition characterized by abnormal fibrosis and impaired vascular function. Pathologically, it encompasses the persistent presence of inflammation, abnormal collagen buildup, and restructuring of blood vessels in various organs, resulting in a wide range of clinical symptoms. This review incorporates the most recent scientific literature on scleroderma, with a particular emphasis on its pathophysiology, clinical manifestations, diagnostic approaches, and treatment options.
Methodology: A comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.
Results: Scleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti-centromere antibodies, and anti-topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.
Discussion: The precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.
Conclusion: Through the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.
Competing Interests: The authors declare no conflict of interest.
(© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.)
Methodology: A comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.
Results: Scleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti-centromere antibodies, and anti-topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.
Discussion: The precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.
Conclusion: Through the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.
Competing Interests: The authors declare no conflict of interest.
(© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.)